Dulaglutide And Glargine in Combination With Prandial Lispro Improved Glycemic Control
Dulaglutide improved balance between the proportion of values within the near-normoglycemia range and values within the hypoglycemic range.
(HealthDay News) – Dulaglutide and glargine in combination with prandial lispro are associated with a similar percentage of time spent in the normoglycemic range, according to a study published in Diabetes, Obesity and Metabolism.
Johan Jendle, MD, PhD, from Örebro University in Sweden, and colleagues randomized 884 conventional insulin regimen-treated patients to dulaglutide 1.5 mg, dulaglutide 0.75 mg, and glargine, in combination with prandial insulin lispro. In a continuous glucose monitoring (CGM) substudy, 144 patients were inserted with a Medtronic CGMS iPro CGM device to enable 3-day glucose monitoring.
The researchers found that mean CGM glucose decreased in all treatment groups (dulaglutide 1.5 mg and 0.75 mg, and glargine) at week 26; the differences between groups were not statistically significant. The percentage time in 3.9 to 7.8 mmol/L range was similar for all treatment groups. The percentage time in 3.9 to 10.0 mmol/L range was greater for dulaglutide 1.5 mg vs glargine (P<.05). For all CGM variability indices, dulaglutide and glargine were associated with decreased glucose variability. Glargine treatment correlated with greater increases in percentage of time with CGM glucose values ≤3.9 mmol/L, with statistically significant between-group differences at 52 weeks (P<.05).
"In combination with prandial lispro, treatment with dulaglutide and glargine resulted in similar proportions of glucose values in the normoglycemic range, but dulaglutide provided an improved balance between the proportion of values within the near-normoglycemia range and values within the hypoglycemic range," the authors write.
Several authors disclosed financial ties to biopharmaceutical companies, including Eli Lilly, which manufactures dulaglutide and funded the study.